EVEREST-1 Phase 1/2 Study for Solid Tumors that Express CEA
EVEREST-1 is a phase 1/2, multi-center, open-label study to evaluate the safety and efficacy of A2B530, an autologous logic-gated Tmod CAR T cell therapy.
EVEREST-1 is currently enrolling patients with non-small cell lung, colorectal, and pancreatic cancers.
Objective: Initially in Phase 1, evaluate the safety and tolerability of A2B530, and identify the maximum tolerated and recommended doses.
Study design: Phase 1/2, US-based, multicenter, open-label, non-randomized, dose-escalation study to evaluate adult patients with recurrent, unresectable, locally advanced, or metastatic non-small cell lung, colorectal, and pancreatic cancers. Participants will initially be enrolled in the BASECAMP-1 prescreening study and leukapheresed before entering EVEREST-1.
Sites recruiting for EVEREST-1 can be found here: Locations
Further information about this study can be found here: NCT05736731